✉news HealthMedicine first seen 4 d ago, last 4 d ago, peak #34
Disc Medicine Shares Jump 32% Before Phase 3 Trial
Original: Disc Medicine (IRON) Surges 32% Premarket Ahead of Phase 3 APOLL
Disc Medicine stock rose roughly 32% in premarket trading as investors reacted to news ahead of its Phase 3 APOLLO program. The biotech, focused on blood disorder treatments, is seen as a standout mover in the healthcare space, with traders positioning for potential catalysts from the late-stage trial.
Why now: The sharp premarket surge ahead of a key Phase 3 milestone is drawing investor attention.
Disc MedicineIRON stockAPOLLO trial
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/2852717